2.9100
+0.0800
+(2.83%)
As of 11:52:37 AM EST. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
800.0000
--
--
--
5,210.0000
Operating Expense
213,588.0000
191,292.0000
116,544.0000
84,474.0000
6,142.0000
Operating Income
-212,788.0000
-191,292.0000
-116,544.0000
-84,474.0000
-932.0000
Other Income Expense
-6,125.0000
-7,120.0000
-6,225.0000
-81,379.0000
-611.0000
Pretax Income
-219,249.0000
-198,412.0000
-122,769.0000
-165,853.0000
-1,543.0000
Tax Provision
--
-279.0000
-948.0000
-486.0000
1,867.0000
Net Income Common Stockholders
-219,249.0000
-198,133.0000
-142,014.0000
-184,119.0000
-5,055.0000
Diluted NI Available to Com Stockholders
-219,249.0000
-198,133.0000
-142,014.0000
-184,119.0000
-5,055.0000
Basic EPS
-2.06
-2.18
-4.19
-2.56
-0.07
Diluted EPS
-2.06
-2.18
-4.19
-2.56
-0.07
Basic Average Shares
108,986.2400
90,969.3270
33,891.2640
71,795.5140
71,795.5140
Diluted Average Shares
108,986.2400
90,969.3270
33,891.2640
71,795.5140
71,795.5140
Total Operating Income as Reported
-226,288.0000
-204,792.0000
-116,544.0000
-84,474.0000
-932.0000
Total Expenses
213,588.0000
191,292.0000
116,544.0000
84,474.0000
6,142.0000
Net Income from Continuing & Discontinued Operation
-219,249.0000
-198,133.0000
-121,821.0000
-165,367.0000
-3,410.0000
Normalized Income
-205,840.0000
-182,266.8820
-113,749.8960
-164,977.1730
-11,342.9100
EBIT
-212,788.0000
-191,292.0000
-116,544.0000
-84,474.0000
-932.0000
EBITDA
-207,130.0000
-186,639.0000
-114,320.0000
-83,906.0000
-889.0000
Reconciled Depreciation
5,658.0000
4,653.0000
2,224.0000
568.0000
43.0000
Net Income from Continuing Operation Net Minority Interest
-219,249.0000
-198,133.0000
-121,821.0000
-165,367.0000
-3,410.0000
Total Unusual Items Excluding Goodwill
-13,409.0000
-15,882.0000
-8,128.0000
-391.0000
10,867.0000
Total Unusual Items
-13,409.0000
-15,882.0000
-8,128.0000
-391.0000
10,867.0000
Normalized EBITDA
-193,721.0000
-170,757.0000
-106,192.0000
-83,515.0000
-11,756.0000
Tax Rate for Calcs
--
0.0000
0.0000
0.0000
0.0003
Tax Effect of Unusual Items
--
-15.8820
-56.8960
-1.1730
2,934.0900
12/31/2020 - 10/20/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BEAM Beam Therapeutics Inc.
27.59
+1.14%
VERV Verve Therapeutics, Inc.
7.73
+4.32%
CRBU Caribou Biosciences, Inc.
1.4950
+14.12%
NTLA Intellia Therapeutics, Inc.
10.59
+0.76%
IPSC Century Therapeutics, Inc.
0.8515
+0.18%
ABSI Absci Corporation
3.8356
+0.41%
RLAY Relay Therapeutics, Inc.
4.6300
+1.98%
SANA Sana Biotechnology, Inc.
3.5450
+1.58%
EDIT Editas Medicine, Inc.
1.3790
+0.66%
FDMT 4D Molecular Therapeutics, Inc.
5.53
-1.22%